4.1 Review

Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents

Journal

METABOLIC SYNDROME AND RELATED DISORDERS
Volume 12, Issue 1, Pages 1-10

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/met.2013.0090

Keywords

-

Funding

  1. Astra-Zeneca
  2. Bracco
  3. Bromatech
  4. Chiesi Farmaceutici
  5. Novartis
  6. Novo-Nordisk
  7. Rikrea
  8. Servier

Ask authors/readers for more resources

Adipose tissue is an endocrine organ that secretes a number of hormones and metabolically active substances that impact energy metabolism and insulin sensitivity. These inflammatory markers are collectively referred to as adipocytokines, or adipokines. Adipose tissue's functional capacity and metabolic activity vary among individuals, thus partly explaining the incomplete overlap between obesity and the metabolic syndrome. The functional failure of adipose tissues results in changed energy delivery and impaired glucose consumption, triggering self-regulatory mechanisms to maintain homeostasis. Antihyperglycemic, hypolipidemic, antiobesity, and angiotensin II receptor blocker drugs influence adipokine levels in different ways. However, clinical data are still scarce and the clinical relevance of these effects needs to be fully determined.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available